摘要
目的:观察罗格列酮联用二甲双胍治疗2型糖尿病(T2DM)的疗效与安全性。方法:将100例初诊的T2DM患者随机分为实验组(A组)和对照组(B组)。在饮食和运动的前提下,A组采用罗格列酮联用二甲双胍治疗,患者口服罗格列酮4mg,qd;二甲双胍0.5g,tid。B组采用格列奇特缓释片联用二甲双胍组治疗,患者口服格列奇特缓释片30mg,qd;二甲双胍0.5g,tid。治疗12周后,检测各组患者治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、空腹胰岛素(FIns)、餐后2h胰岛素(2hIns)、糖化血红蛋白(HBA1C)、体质量指数(BMI)、超敏C反应蛋白(hs-CRP)水平,并计算胰岛素抵抗指数(HOMA-IR)。结果:治疗12周后,2组患者的PG、HBA1C、BMI、CRP均下降(P<0.05),但A组CRP较B组下降差异有显著性(P<0.05)。A组治疗后Ins、2hIns、HOMA-IR较前均有显著性降低(P<0.01);而B组下降不明显,差异无显著性。2组间FIns、2hIns、HOMA-IR比较差异有显著性(P<0.01)。结论:罗格列酮联用二甲双胍治疗T2DM可较好地控制血糖,减轻体质量,同时改善胰岛素抵抗(IR),降低患者机体的炎症状态,具有明显的抗炎作用。
OBJECTIVE To observe the efficacy and safety of rosiglitazone combined with metformin in the treatment of type 2 diabetes mellitus. METHODS 100 patients with newly diagnosed type 2 diabetes were randomly divided into test group （group A） and control group （group B）. Group A were treated with rosiglitazone and metformin and group B were treated with gliclazide tablets and metformin. In the premise of the diet and movement, group A was administered with rosiglitazone 4 mg, qd; metformin 0.5 g, tid. Group B was administered with gliclazide tablets 30 mg, qd; metformin 0.5 g,tid. All patiens were treated for 12 weeks, fasting plasma glucose, two-hour postprandial plasma glucose, fasting insulin, two-hour postprandial in sulin, glycosylated hemoglobin HB A1 C, body mass index and high sensitivity C-reaclive proteln were observed before and after treatment, and the HOMA-insulin resistance index was calculated. RESULTS After 12 weeks, the PG, HBA1C, BMI and hs- CRP were decreased in each group, but the hs CRP in group A was significantly decreased compared with group 13 （P〈0.05）, After treatment, the PG, HBA1 C, BMI and hs-CRP were decreased in each group, but the hs CRP in group A was significantly decreased compared with group B （P〈0. {15）. The Ins and HOMA-IR were both significantly lower in group A （P〈0. 01 ）. But group 13 did not decrease obviously. However, there was a significant difference on the levels of Fins, 2hlns and H（）MA- IR between two groups （P〈0. 01 ）. CONCLUSION Rosiglitazone combined with metformin can achieve better control of blood glucose, body weight, and insulin resistance, and exert obvious anti inflammatory effect in the treatment of T2DM.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2010年第22期1933-1935,共3页
Chinese Journal of Hospital Pharmacy
